NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
6
Data completeness
7/8 — Comprehensive
ACUVAIL (ketorolac tromethamine) by AbbVie is anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. Approved for postoperative pain, postoperative inflammation. First approved in 2009.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACUVAIL is a topical ophthalmic solution containing ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin biosynthesis. It is indicated for postoperative pain and inflammation, allergic conjunctivitis, and other ocular conditions. The drug delivers anti-inflammatory and analgesic activity directly to the eye via topical drops.
$0.174MPart D
Peak3.3 years to LOEACUVAIL is in peak lifecycle with modest Part D spending ($174K in 2023); brand team is likely focused on maintaining market share against rising competitive pressure (8/10).
Mechanism of Action
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Indications (2)
Clinical Trials (6)
Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
Started Mar 2013
83 enrolled
Back Pain
Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Started Mar 2013
78 enrolled
Back Pain
Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
Started Dec 2010
129 enrolled
Rhinitis, Allergic, SeasonalConjunctivitis, Allergic
A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing
Started Aug 2010
10 enrolled
Must be PRK Candidate
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Started Oct 2009
126 enrolled
Cataracts
Worked on ACUVAIL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.